시장보고서
상품코드
1150079

세계의 편두통 치료제 시장 - 시장 점유율, 규모, 동향, 업계 분석 : 제품 유형별, 치료 클래스별, 투여 경로별, 최종 용도별, 지역별, 부문 예측(2022-2030년)

Migraine Drugs Market Share, Size, Trends, Industry Analysis Report, By Product Type (Acute/Abortive Treatment, Preventive/Prophylactic Treatment); By Therapeutic Class; By Route of Administration; By End-Use; By Region; Segment Forecast, 2022 - 2030

발행일: | 리서치사: Polaris Market Research | 페이지 정보: 영문 118 Pages | 배송안내 : 1-2일 (영업일 기준)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 편두통 치료제 시장 규모는 2030년까지 87억 9,000만 달러에 이를 것으로 예측됩니다.

세계의 편두통(Migraine) 치료제 시장을 조사했으며, 시장 개요, 시장 규모와 예측, 동향, 성장 촉진요인 및 억제요인, 제품 유형별·치료 클래스별·투여 경로별·최종 용도별·지역별 등의 분석, 기업 개요 등의 정보를 제공합니다.

목차

제1장 서론

  • 보고서 설명
    • 조사 목적
    • 시장 범위
    • 전제조건
  • 이해관계자

제2장 주요 요약

  • 시장 하이라이트

제3장 조사 방법

  • 개요
    • 데이터 마이닝
  • 정보원
    • 1차 정보
    • 2차 정보

제4장 세계의 편두통 치료제 시장 인사이트

  • 편두통 치료제 - 업계 현황
  • 편두통 치료제 시장 역학
    • 성장 촉진요인과 기회
    • 성장 억제요인과 과제
  • Porter의 산업 분석
    • 공급 기업의 교섭력
    • 신규 진출기업의 위협
    • 바이어의 교섭력
    • 대체품의 위협
    • 기존 기업간 경쟁력
  • PESTLE 분석
  • 편두통 치료제 업계 동향
  • 밸류체인 분석
  • COVID-19의 영향 분석

제5장 세계의 편두통 치료제 시장 : 제품 유형별

  • 주요 조사 결과
  • 서론
    • 세계의 편두통 치료제 시장, 제품 유형별(2018-2030년)
  • 급성 치료제/부전요법(Abortive Treatment)
    • 세계의 편두통 치료제 시장, 급성 치료제/부전요법, 지역별(2018-2030년)
  • 예방약/예방 치료제
    • 세계의 편두통 치료제 시장, 예방약/예방 치료제별, 지역별(2018-2030년)

제6장 세계의 편두통 치료제 시장 : 치료 클래스별

  • 주요 조사 결과
  • 서론
    • 세계의 편두통 치료제 시장, 치료 클래스별(2018-2030년)
  • Triptans
    • 세계의 편두통 치료제 시장, Triptans, 지역별(2018-2030년)
  • 아세틸콜린 저해제/neurotoxins
    • 세계의 편두통 치료제 시장, 아세틸콜린 저해제/neurotoxins, 지역별(2018-2030년)
  • Ergot Alkaloids
    • 세계의 편두통 치료제 시장, Ergot Alkaloids, 지역별(2018-2030년)
  • NSAID
    • 세계의 편두통 치료제 시장, NSAID, 지역별(2018-2030년)
  • Ditans
    • 세계의 편두통 치료제 시장, Ditans, 지역별(2018-2030년)
  • CGRP small molecule antagonists
    • 세계의 편두통 치료제 시장, CGRP small molecule antagonists, 지역별(2018-2030년)
  • CGRP 단클론항체
    • 세계의 편두통 치료제 시장, CGRP 단클론항체, 지역별(2018-2030년)
  • 기타
    • 세계의 편두통 치료제 시장, 기타, 지역별(2018-2030년)

제7장 세계의 편두통 치료제 시장 : 투여 경로별

  • 주요 조사 결과
  • 서론
    • 세계의 편두통 치료제 시장, 투여 경로별(2018-2030년)
  • 경구
    • 세계의 편두통 치료제 시장, 경구, 지역별(2018-2030년)
  • 주사
    • 세계의 편두통 치료제 시장, 주사, 지역별(2018-2030년)
  • 기타
    • 세계의 편두통 치료제 시장, 기타, 지역별(2018-2030년)

제8장 세계의 편두통 치료제 시장 : 최종 용도별

  • 주요 조사 결과
  • 서론
    • 세계의 편두통 치료제 시장, 최종 용도별(2018-2030년)
  • 병원 약국
    • 세계의 편두통 치료제 시장, 병원 약국, 지역별(2018-2030년)
  • 소매 약국
    • 세계의 편두통 치료제 시장, 소매 약국, 지역별(2018-2030년)
  • 온라인 약국
    • 세계의 편두통 치료제 시장, 온라인 약국, 지역별(2018-2030년)

제9장 세계의 편두통 치료제 시장 : 지역별

  • 주요 조사 결과
  • 서론
    • 편두통 치료제 시장 평가, 지역별(2018-2030년)
  • 편두통 치료제 시장 - 북미
    • 북미 : 편두통 치료제 시장, 제품 유형별(2018-2030년)
    • 북미 : 편두통 치료제 시장, 최종 용도별(2018-2030년)
    • 북미 : 편두통 치료제 시장, 치료 클래스별(2018-2030년)
    • 북미 : 편두통 치료제 시장, 투여 경로별(2018-2030년)
    • 편두통 치료제 시장 - 미국
    • 편두통 치료제 시장 - 캐나다
  • 편두통 치료제 시장 - 유럽
    • 유럽 : 편두통 치료제 시장, 제품 유형별(2018-2030년)
    • 유럽 : 편두통 치료제 시장, 최종 용도별(2018-2030년)
    • 유럽 : 편두통 치료제 시장, 치료 클래스별(2018-2030년)
    • 유럽 : 편두통 치료제 시장, 투여 경로별(2018-2030년)
    • 편두통 치료제 시장 - 영국
    • 편두통 치료제 시장 - 프랑스
    • 편두통 치료제 시장 - 독일
    • 편두통 치료제 시장 - 이탈리아
    • 편두통 치료제 시장 - 스페인
    • 편두통 치료제 시장 - 네덜란드
    • 편두통 치료제 시장 - 러시아
  • 편두통 치료제 시장 - 아시아태평양
    • 아시아태평양 : 편두통 치료제 시장, 제품 유형별(2018-2030년)
    • 아시아태평양 : 편두통 치료제 시장, 최종 용도별(2018-2030년)
    • 아시아태평양 : 편두통 치료제 시장, 치료 클래스별(2018-2030년)
    • 아시아태평양 : 편두통 치료제 시장, 투여 경로별(2018-2030년)
    • 편두통 치료제 시장 - 중국
    • 편두통 치료제 시장 - 인도
    • 편두통 치료제 시장 - 일본
    • 편두통 치료제 시장 - 말레이시아
    • 편두통 치료제 시장 - 인도네시아
    • 편두통 치료제 시장 - 한국
  • 편두통 치료제 시장 - 중동 및 아프리카
    • 중동 및 아프리카 : 편두통 치료제 시장, 제품 유형별(2018-2030년)
    • 중동 및 아프리카 : 편두통 치료제 시장, 최종 용도별(2018-2030년)
    • 중동 및 아프리카 : 편두통 치료제 시장, 치료 클래스별(2018-2030년)
    • 중동 및 아프리카 : 편두통 치료제 시장, 투여 경로별(2018-2030년)
    • 편두통 치료제 시장 - 사우디아라비아
    • 편두통 치료제 시장 - 남아프리카공화국
    • 편두통 치료제 시장 - 이스라엘
    • 편두통 치료제 시장 - 아랍에미리트(UAE)
  • 편두통 치료제 시장 - 라틴아메리카
    • 라틴아메리카 : 편두통 치료제 시장, 제품 유형별, 2018년부터 2030년
    • 라틴아메리카 : 편두통 치료제 시장, 최종 용도별(2018-2030년)
    • 라틴아메리카 : 편두통 치료제 시장, 치료 클래스별(2018-2030년)
    • 라틴아메리카 : 편두통 치료제 시장, 투여 경로별(2018-2030년)
    • 편두통 치료제 시장 - 멕시코
    • 편두통 치료제 시장 - 브라질
    • 편두통 치료제 시장 - 아르헨티나

제10장 경쟁 구도

  • 확장 및 인수 분석
    • 확장
    • 인수
  • 파트너십/협업/협정/공개

제11장 기업 개요

  • Allergan Plc
  • Alder Biopharmaceuticals Inc.
  • AstraZeneca PLC
  • Amgen Inc
  • eNeura Inc
  • Endo Pharmaceuticals Inc
  • Eli Lilly and Company
  • GlaxoSmithKline Plc
  • Johnson & Johnson Services Inc
  • Merck & Co. Inc
  • Pfizer Inc
  • Teva Pharmaceutical Industries Ltd
LSH 22.12.02

The global Migraine Drugs market size is expected to reach USD 8.79 billion by 2030, according to a new study by Polaris Market Research. The report "Migraine Drugs Market Share, Size, Trends, Industry Analysis Report, By Product Type (Acute/Abortive Treatment, Preventive/Prophylactic Treatment); By Therapeutic Class; By Route of Administration; By End-Use; By Region; Segment Forecast, 2022 - 2030" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The increasing prevalence of neurological illnesses such as migraine among the teenage population as a result of a more sedentary lifestyle is expected to boost the market growth in the future years.

For instance, according to the National Institute of Health, Migraine affects about one billion people worldwide each year and is one of the most frequent neurologic illnesses, with a higher incidence and morbidity, especially among young people and females. From 1990 to 2019, the worldwide age-standardized frequency of migraine grew by 1.7%, with 1.1 billion prevalent instances in 2019.

Moreover, the increasing launch of Calcitonin gene-related peptide (CGRP)-based medicines and significant unmet requirements are some of the important reasons driving market expansion. For instance, in December 2019, Ubrelvy (ubrogepant) tablets were approved by the Food and Drug Administration for the acute (immediate) therapy of migraine, either with or without vision in adults.

Ubrelvy is not approved for the prevention of migraines. It is the first medicine licensed for the acute treatment of migraines in the category of oral calcitonin gene-related peptides (CGRP) antagonists. Thus, this rising prevalence, along with the increasing approvals, is driving market growth over the forecast period.

Furthermore, an increase in females number and a rise in patient awareness about migraine prevention and treatment are major drivers driving the market growth. Migraine headaches are more common in women than in men. According to the National Institute of Health of Migraine Association of Ireland, the global population in 2018 had a female migraineur to male migraineur ratio of 3:1. This is due to variations in estrogen levels in females, particularly during menstruation.

Furthermore, hormonal drugs, including oral contraceptives and hormone replacement treatment, may aggravate migraine in women. As a result, an increase in the worldwide female population is expected to drive the market growth of the migraine drugs.

Migraine Drugs Market Report Highlights

Online pharmacy segment is expected to grow at a significant CAGR over the forecast period. It is the quickest segment, offering migraine drugs through e-commerce platforms. The majority of the drugs given by online pharmacy chains are for the treatment of severe migraines.

Preventive/ Prophylactic Treatment segment accounted for a lucrative revenue share. Migraine prevention methods lessen migraine frequency and severity. Beta-blockers, botulism toxin toxins, and topiramate are the main pharmacological types used in preventive therapy.

Asia Pacific is expected to grow at a significant CAGR over the projected period. The Asia Pacific region is expected to grow significantly in the future, due to increased demand for improved health centers and improvements in the healthcare system.

The global players include Allergan, Alder Biopharmaceuticals, AstraZeneca, Amgen Inc., eNeura Inc., Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson, Merck, Pfizer, and Teva Pharmaceutical.

Polaris Market Research has segmented the migraine drugs market report based on product type, therapeutic class, end-use, route of administration, and region:

Migraine Drugs, Product Type Outlook (Revenue - USD Billion, 2018 - 2030)

Acute / Abortive Treatment

Preventive/ Prophylactic Treatment

Migraine Drugs, Therapeutic Class Outlook (Revenue - USD Billion, 2018 - 2030)

Triptans

Acetylcholine Inhibitors/ neurotoxins

Ergot Alkaloids

NSAIDs

Ditans

CGRP small molecule antagonists

CGRP monoclonal antibodies

Others

Migraine Drugs, Route of Administration Outlook (Revenue - USD Billion, 2018 - 2030)

Oral

Injectables

Others

Migraine Drugs, End-Use Outlook (Revenue - USD Billion, 2018 - 2030)

Hospital pharmacies

Retail pharmacies

Online pharmacies

Migraine Drugs, Regional Outlook (Revenue - USD Billion, 2018 - 2030)

North America

U.S

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Latin America

Argentina

Brazil

Mexico

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Migraine Drugs Market Insights

  • 4.1. Migraine Drugs - Industry Snapshot
  • 4.2. Migraine Drugs Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increase in prevalence of migraine
      • 4.2.1.2. Rise in awareness among patients toward migraine treatment and prevention
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Side effects of migraine drug
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Migraine Drugs Industry Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Migraine Drugs Market, by Product Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
  • 5.3. Acute/Abortive Treatment
    • 5.3.1. Global Migraine Drugs Market, by Acute/Abortive Treatment, by Region, 2018 - 2030 (USD Billion)
  • 5.4. Preventive/ Prophylactic Treatment
    • 5.4.1. Global Migraine Drugs Market, by Preventive/ Prophylactic Treatment, by Region, 2018 - 2030 (USD Billion)

6. Global Migraine Drugs Market, by Therapeutic Class

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
  • 6.3. Triptans
    • 6.3.1. Global Migraine Drugs Market, by Triptans, by Region, 2018 - 2030 (USD Billion)
  • 6.4. Acetylcholine Inhibitors/ neurotoxins
    • 6.4.1. Global Migraine Drugs Market, by Acetylcholine Inhibitors/ neurotoxins, by Region, 2018 - 2030 (USD Billion)
  • 6.5. Ergot Alkaloids
    • 6.5.1. Global Migraine Drugs Market, by Ergot Alkaloids, by Region, 2018 - 2030 (USD Billion)
  • 6.6. NSAIDs
    • 6.6.1. Global Migraine Drugs Market, by NSAIDs, by Region, 2018 - 2030 (USD Billion)
  • 6.7. Ditans
    • 6.7.1. Global Migraine Drugs Market, by Ditans, by Region, 2018 - 2030 (USD Billion)
  • 6.8. CGRP small molecule antagonists
    • 6.8.1. Global Migraine Drugs Market, by CGRP small molecule antagonists, by Region, 2018 - 2030 (USD Billion)
  • 6.9. CGRP monoclonal antibodies
    • 6.9.1. Global Migraine Drugs Market, by CGRP monoclonal antibodies, by Region, 2018 - 2030 (USD Billion)
  • 6.10. Others
    • 6.10.1. Global Migraine Drugs Market, by Others, by Region, 2018 - 2030 (USD Billion)

7. Global Migraine Drugs Market, by Route of Administration

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • 7.3. Oral
    • 7.3.1. Global Migraine Drugs Market, by Oral, by Region, 2018 - 2030 (USD Billion)
  • 7.4. Injectables
    • 7.4.1. Global Migraine Drugs Market, by Injectables, by Region, 2018 - 2030 (USD Billion)
  • 7.5. Others
    • 7.5.1. Global Migraine Drugs Market, by Others, by Region, 2018 - 2030 (USD Billion)

8. Global Migraine Drugs Market, by End-Use

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Global Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
  • 8.3. Hospital pharmacies
    • 8.3.1. Global Migraine Drugs Market, by Hospital pharmacies, by Region, 2018 - 2030 (USD Billion)
  • 8.4. Retail pharmacies
    • 8.4.1. Global Migraine Drugs Market, by Retail pharmacies, by Region, 2018 - 2030 (USD Billion)
  • 8.5. Online pharmacies
    • 8.5.1. Global Migraine Drugs Market, by Online pharmacies, by Region, 2018 - 2030 (USD Billion)

9. Global Migraine Drugs Market, by Geography

  • 9.1. Key findings
  • 9.2. Introduction
    • 9.2.1. Migraine Drugs Market Assessment, By Geography, 2018 - 2030 (USD Billion)
  • 9.3. Migraine Drugs Market - North America
    • 9.3.1. North America: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
    • 9.3.2. North America: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
    • 9.3.3. North America: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
    • 9.3.4. North America: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.3.5. Migraine Drugs Market - U.S.
      • 9.3.5.1. U.S.: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
      • 9.3.5.2. U.S.: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
      • 9.3.5.3. U.S.: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
      • 9.3.5.4. U.S.: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.3.6. Migraine Drugs Market - Canada
      • 9.3.6.1. Canada: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
      • 9.3.6.2. Canada: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
      • 9.3.6.3. Canada: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
      • 9.3.6.4. Canada: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • 9.4. Migraine Drugs Market - Europe
    • 9.4.1. Europe: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
    • 9.4.2. Europe: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
    • 9.4.3. Europe: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
    • 9.4.4. Europe: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.4.5. Migraine Drugs Market - UK
      • 9.4.5.1. UK: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
      • 9.4.5.2. UK: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
      • 9.4.5.3. UK: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
      • 9.4.5.4. UK: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.4.6. Migraine Drugs Market - France
      • 9.4.6.1. France: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
      • 9.4.6.2. France: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
      • 9.4.6.3. France: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
      • 9.4.6.4. France: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.4.7. Migraine Drugs Market - Germany
      • 9.4.7.1. Germany: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
      • 9.4.7.2. Germany: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
      • 9.4.7.3. Germany: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
      • 9.4.7.4. Germany: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.4.8. Migraine Drugs Market - Italy
      • 9.4.8.1. Italy: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
      • 9.4.8.2. Italy: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
      • 9.4.8.3. Italy: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
      • 9.4.8.4. Italy: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.4.9. Migraine Drugs Market - Spain
      • 9.4.9.1. Spain: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
      • 9.4.9.2. Spain: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
      • 9.4.9.3. Spain: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
      • 9.4.9.4. Spain: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.4.10. Migraine Drugs Market - Netherlands
      • 9.4.10.1. Netherlands: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
      • 9.4.10.2. Netherlands: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
      • 9.4.10.3. Netherlands: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
      • 9.4.10.4. Netherlands: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.4.11. Migraine Drugs Market - Russia
      • 9.4.11.1. Russia: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
      • 9.4.11.2. Russia.: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
      • 9.4.11.3. Russia: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
      • 9.4.11.4. Russia: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • 9.5. Migraine Drugs Market - Asia Pacific
    • 9.5.1. Asia Pacific: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
    • 9.5.2. Asia Pacific: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
    • 9.5.3. Asia Pacific: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
    • 9.5.4. Asia Pacific: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.5.5. Migraine Drugs Market - China
      • 9.5.5.1. China: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
      • 9.5.5.2. China.: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
      • 9.5.5.3. China: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
      • 9.5.5.4. China: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.5.6. Migraine Drugs Market - India
      • 9.5.6.1. India: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
      • 9.5.6.2. India.: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
      • 9.5.6.3. India: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
      • 9.5.6.4. India: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.5.7. Migraine Drugs Market - Japan
      • 9.5.7.1. Japan: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
      • 9.5.7.2. Japan.: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
      • 9.5.7.3. Japan: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
      • 9.5.7.4. Japan: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.5.8. Migraine Drugs Market - Malaysia
      • 9.5.8.1. Malaysia: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
      • 9.5.8.2. Malaysia.: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
      • 9.5.8.3. Malaysia: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
      • 9.5.8.4. Malaysia: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.5.9. Migraine Drugs Market - Indonesia
      • 9.5.9.1. Indonesia: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
      • 9.5.9.2. Indonesia.: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
      • 9.5.9.3. Indonesia: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
      • 9.5.9.4. Indonesia: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.5.10. Migraine Drugs Market - South Korea
      • 9.5.10.1. South Korea: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
      • 9.5.10.2. South Korea.: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
      • 9.5.10.3. South Korea: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
      • 9.5.10.4. South Korea: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • 9.6. Migraine Drugs Market - Middle East & Africa
    • 9.6.1. Middle East & Africa: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
    • 9.6.2. Middle East & Africa: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
    • 9.6.3. Middle East & Africa: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
    • 9.6.4. Middle East & Africa: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.6.5. Migraine Drugs Market - Saudi Arabia
      • 9.6.5.1. Saudi Arabia: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
      • 9.6.5.2. Saudi Arabia: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
      • 9.6.5.3. Saudi Arabia: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
      • 9.6.5.4. Saudi Arabia: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.6.6. Migraine Drugs Market - South Africa
      • 9.6.6.1. South Africa: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
      • 9.6.6.2. South Africa: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
      • 9.6.6.3. South Africa: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
      • 9.6.6.4. South Africa: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.6.7. Migraine Drugs Market - Israel
      • 9.6.7.1. Israel: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
      • 9.6.7.2. Israel: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
      • 9.6.7.3. Israel: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
      • 9.6.7.4. Israel: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.6.8. Migraine Drugs Market - UAE
      • 9.6.8.1. UAE: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
      • 9.6.8.2. UAE: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
      • 9.6.8.3. UAE: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
      • 9.6.8.4. UAE: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • 9.7. Migraine Drugs Market - Latin America
    • 9.7.1. Latin America: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
    • 9.7.2. Latin America: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
    • 9.7.3. Latin America: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
    • 9.7.4. Latin America: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.7.5. Migraine Drugs Market - Mexico
      • 9.7.5.1. Mexico: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
      • 9.7.5.2. Mexico: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
      • 9.7.5.3. Mexico: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
      • 9.7.5.4. Mexico: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.7.6. Migraine Drugs Market - Brazil
      • 9.7.6.1. Brazil: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
      • 9.7.6.2. Brazil: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
      • 9.7.6.3. Brazil: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
      • 9.7.6.4. Brazil: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.7.7. Migraine Drugs Market - Argentina
      • 9.7.7.1. Argentina: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
      • 9.7.7.2. Argentina: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
      • 9.7.7.3. Argentina: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
      • 9.7.7.4. Argentina: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)

10. Competitive Landscape

  • 10.1. Expansion and Acquisition Analysis
    • 10.1.1. Expansion
    • 10.1.2. Acquisitions
  • 10.2. Partnerships/Collaborations/Agreements/Exhibitions

11. Company Profiles

  • 11.1. Allergan Plc
    • 11.1.1. Company Overview
    • 11.1.2. Financial Performance
    • 11.1.3. Product Benchmarking
    • 11.1.4. Recent Development
  • 11.2. Alder Biopharmaceuticals Inc.
    • 11.2.1. Company Overview
    • 11.2.2. Financial Performance
    • 11.2.3. Product Benchmarking
    • 11.2.4. Recent Development
  • 11.3. AstraZeneca PLC
    • 11.3.1. Company Overview
    • 11.3.2. Financial Performance
    • 11.3.3. Product Benchmarking
    • 11.3.4. Recent Development
  • 11.4. Amgen Inc
    • 11.4.1. Company Overview
    • 11.4.2. Financial Performance
    • 11.4.3. Product Benchmarking
    • 11.4.4. Recent Development
  • 11.5. eNeura Inc
    • 11.5.1. Company Overview
    • 11.5.2. Financial Performance
    • 11.5.3. Product Benchmarking
    • 11.5.4. Recent Development
  • 11.6. Endo Pharmaceuticals Inc
    • 11.6.1. Company Overview
    • 11.6.2. Financial Performance
    • 11.6.3. Product Benchmarking
    • 11.6.4. Recent Development
  • 11.7. Eli Lilly and Company
    • 11.7.1. Company Overview
    • 11.7.2. Financial Performance
    • 11.7.3. Product Benchmarking
    • 11.7.4. Recent Development
  • 11.8. GlaxoSmithKline Plc
    • 11.8.1. Company Overview
    • 11.8.2. Financial Performance
    • 11.8.3. Product Benchmarking
    • 11.8.4. Recent Development
  • 11.9. Johnson & Johnson Services Inc
    • 11.9.1. Company Overview
    • 11.9.2. Financial Performance
    • 11.9.3. Product Benchmarking
    • 11.9.4. Recent Development
  • 11.10. Merck & Co. Inc
    • 11.10.1. Company Overview
    • 11.10.2. Financial Performance
    • 11.10.3. Product Benchmarking
    • 11.10.4. Recent Development
  • 11.11. Pfizer Inc
    • 11.11.1. Company Overview
    • 11.11.2. Financial Performance
    • 11.11.3. Product Benchmarking
    • 11.11.4. Recent Development
  • 11.12. Teva Pharmaceutical Industries Ltd
    • 11.12.1. Company Overview
    • 11.12.2. Financial Performance
    • 11.12.3. Product Benchmarking
    • 11.12.4. Recent Development
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제